TScan Therapeutics’ (TCRX) “Outperform” Rating Reiterated at Wedbush

Wedbush reissued their outperform rating on shares of TScan Therapeutics (NASDAQ:TCRX) in a research note issued to investors on Monday morning,RTT News reports. The brokerage currently has a $7.00 target price on the stock.

Several other research firms have also weighed in on TCRX. Needham & Company LLC reiterated a “buy” rating and set a $11.00 target price on shares of TScan Therapeutics in a report on Wednesday, December 11th. HC Wainwright reiterated a “buy” rating and set a $15.00 price objective on shares of TScan Therapeutics in a report on Wednesday, December 11th.

TScan Therapeutics Stock Performance

Shares of TCRX stock opened at $2.91 on Monday. The stock has a market cap of $155.31 million, a PE ratio of -2.75 and a beta of 0.79. The stock has a 50-day moving average of $4.41 and a 200-day moving average of $5.54. The company has a debt-to-equity ratio of 0.13, a current ratio of 9.56 and a quick ratio of 9.56. TScan Therapeutics has a one year low of $2.60 and a one year high of $9.69.

TScan Therapeutics (NASDAQ:TCRX) last issued its earnings results on Tuesday, November 12th. The company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.28) by $0.03. The firm had revenue of $1.05 million during the quarter, compared to the consensus estimate of $2.86 million. TScan Therapeutics had a negative net margin of 1,188.88% and a negative return on equity of 58.72%. As a group, sell-side analysts expect that TScan Therapeutics will post -1.12 earnings per share for the current year.

Institutional Trading of TScan Therapeutics

A number of institutional investors have recently modified their holdings of TCRX. Dimensional Fund Advisors LP bought a new stake in TScan Therapeutics in the 2nd quarter valued at approximately $70,000. SG Americas Securities LLC acquired a new stake in shares of TScan Therapeutics in the third quarter valued at approximately $78,000. The Manufacturers Life Insurance Company bought a new stake in shares of TScan Therapeutics in the second quarter worth $90,000. XTX Topco Ltd acquired a new position in TScan Therapeutics during the third quarter worth $112,000. Finally, MetLife Investment Management LLC grew its position in TScan Therapeutics by 129.1% in the third quarter. MetLife Investment Management LLC now owns 23,363 shares of the company’s stock valued at $116,000 after purchasing an additional 13,164 shares in the last quarter. 82.83% of the stock is currently owned by institutional investors.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.